Post by Hot Christian Stocks on Apr 23, 2012 9:33:17 GMT -5
PYMX - PolyMedix, Inc.
PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of acute care conditions. Based on its proprietary drug discovery platform, PolyMedix has created a robust pipeline of innovative product candidates for treating patients with cardiovascular conditions and infectious diseases. In addition, PolyMedix is leveraging its antimicrobial expertise by developing PolyCides, antimicrobial additives to materials, such as cosmetics, plastics and textiles, to create self-sterilizing products and surfaces.
Contact Info
170 N. Radnor-Chester Road
Suite 300
Radnor, PA 19087
Website: www.polymedix.com
Phone: 484-598-2400
Email: lcaperelli@polymedix.com
www.otcmarkets.com/stock/PYMX/company-info
Nicholas Landekic
President, Chief Executive Officer and Director
Nicholas Landekic is a Founder of PolyMedix and has served as President, Chief Executive Officer and Director since inception in 2002. Under his leadership, PolyMedix has internally built a pipeline of cardiovascular and infectious disease drugs, with lead candidates from each program in Phase 2 clinical trials. Since starting PolyMedix, Mr. Landekic has successfully secured over $115 million in funding from public and private capital raises and government contracts and grants. For the past 25 years, Mr. Landekic has held leadership positions in business development, marketing, and finance with biotechnology and pharmaceutical companies. Prior to PolyMedix, Mr. Landekic was President and Chief Executive Officer of Locus Discovery, and also held positions in Corporate/Business Development, Strategic Marketing, and Finance at Guilford Pharmaceuticals, Cephalon, Bristol-Myers Squibb and Johnson & Johnson Corporation (McNeil Pharmaceutical). Earlier in his career, he worked in the research laboratories at Mt. Sinai Medical Center. Mr. Landekic received an MBA from the State University of New York at Albany, an M.A. in Biology from Indiana University and a B.S. in Biology from Marist College.
www.polymedix.com/company-profile/management/bio/nicholas-landekic
Pipeline
www.polymedix.com/pipeline
"Our mission is to save patients’ lives and transform the management of medicine by cost-efficiently developing novel, innovative therapies for life-threatening conditions with significant unmet medical needs. We strive to achieve this goal through our commitment to excellence in research and clinical development"
PolyMedix is a clinical stage biotechnology company that is developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. Using our proprietary drug discovery platform, we have internally created a pipeline of innovative infectious disease and cardiovascular products that meet the following criteria:
Address large market opportunities
Therapeutic areas with efficient, inexpensive development paths
Clear clinical endpoints
Early clinical proof of concept
The lead compound in our infectious disease program is PMX-30063, the first drug of a completely new class of antibiotics, the defensin-mimetics. Our defensin-mimetic antibiotics are designed to imitate the mechanism of natural human immunity – the host defense proteins. By mimicking the mechanism of action of the host defense proteins, PMX-30063 works completely differently from known biochemical antibiotics, and exploits a method of bacterial cell killing that significantly reduces the risk of bacterial resistance. We have recently completed a multinational Phase 2 clinical trial with PMX-30063 to treat patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus bacteria, including methicillin-resistant S. aureus (MRSA).
The lead compound in our cardiovascular program is PMX-60056, which is an anticoagulant reversing agent designed to restore coagulation to help better manage the balance between preventing blood clots and mitigating bleeding in interventional cardiology procedures, as well as emergency situations where patients are on the anticoagulant drugs heparin and low molecular weight heparins (LMWH). In multiple clinical trials, PMX-60056 has met safety and efficacy endpoints and demonstrated clinical proof of concept. We are currently conducting a Phase 2 clinical trial with PMX-60056 to treat patients undergoing Percutaneous Coronary Intervention (PCI) and a Phase 1B/2 clinical trial to reverse the anticoagulant effect of the LMWH enoxaparin in healthy subjects.
Our preclinical portfolio includes next-generation defensin-mimetic compounds, which have shown potent activity targeting:
Gram-negative bacteria
Tuberculosis
Malaria
Foodborne pathogens
Biodefense pathogens
Fungal infections
We are leveraging our antimicrobial expertise by developing PolyCides®, antimicrobial additives to materials, such as cosmetics, plastics, textiles and dental products (PolyDentix™), to create self-sterilizing products and surfaces.
PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of acute care conditions. Based on its proprietary drug discovery platform, PolyMedix has created a robust pipeline of innovative product candidates for treating patients with cardiovascular conditions and infectious diseases. In addition, PolyMedix is leveraging its antimicrobial expertise by developing PolyCides, antimicrobial additives to materials, such as cosmetics, plastics and textiles, to create self-sterilizing products and surfaces.
Contact Info
170 N. Radnor-Chester Road
Suite 300
Radnor, PA 19087
Website: www.polymedix.com
Phone: 484-598-2400
Email: lcaperelli@polymedix.com
www.otcmarkets.com/stock/PYMX/company-info
Nicholas Landekic
President, Chief Executive Officer and Director
Nicholas Landekic is a Founder of PolyMedix and has served as President, Chief Executive Officer and Director since inception in 2002. Under his leadership, PolyMedix has internally built a pipeline of cardiovascular and infectious disease drugs, with lead candidates from each program in Phase 2 clinical trials. Since starting PolyMedix, Mr. Landekic has successfully secured over $115 million in funding from public and private capital raises and government contracts and grants. For the past 25 years, Mr. Landekic has held leadership positions in business development, marketing, and finance with biotechnology and pharmaceutical companies. Prior to PolyMedix, Mr. Landekic was President and Chief Executive Officer of Locus Discovery, and also held positions in Corporate/Business Development, Strategic Marketing, and Finance at Guilford Pharmaceuticals, Cephalon, Bristol-Myers Squibb and Johnson & Johnson Corporation (McNeil Pharmaceutical). Earlier in his career, he worked in the research laboratories at Mt. Sinai Medical Center. Mr. Landekic received an MBA from the State University of New York at Albany, an M.A. in Biology from Indiana University and a B.S. in Biology from Marist College.
www.polymedix.com/company-profile/management/bio/nicholas-landekic
Pipeline
www.polymedix.com/pipeline
"Our mission is to save patients’ lives and transform the management of medicine by cost-efficiently developing novel, innovative therapies for life-threatening conditions with significant unmet medical needs. We strive to achieve this goal through our commitment to excellence in research and clinical development"
PolyMedix is a clinical stage biotechnology company that is developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. Using our proprietary drug discovery platform, we have internally created a pipeline of innovative infectious disease and cardiovascular products that meet the following criteria:
Address large market opportunities
Therapeutic areas with efficient, inexpensive development paths
Clear clinical endpoints
Early clinical proof of concept
The lead compound in our infectious disease program is PMX-30063, the first drug of a completely new class of antibiotics, the defensin-mimetics. Our defensin-mimetic antibiotics are designed to imitate the mechanism of natural human immunity – the host defense proteins. By mimicking the mechanism of action of the host defense proteins, PMX-30063 works completely differently from known biochemical antibiotics, and exploits a method of bacterial cell killing that significantly reduces the risk of bacterial resistance. We have recently completed a multinational Phase 2 clinical trial with PMX-30063 to treat patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus bacteria, including methicillin-resistant S. aureus (MRSA).
The lead compound in our cardiovascular program is PMX-60056, which is an anticoagulant reversing agent designed to restore coagulation to help better manage the balance between preventing blood clots and mitigating bleeding in interventional cardiology procedures, as well as emergency situations where patients are on the anticoagulant drugs heparin and low molecular weight heparins (LMWH). In multiple clinical trials, PMX-60056 has met safety and efficacy endpoints and demonstrated clinical proof of concept. We are currently conducting a Phase 2 clinical trial with PMX-60056 to treat patients undergoing Percutaneous Coronary Intervention (PCI) and a Phase 1B/2 clinical trial to reverse the anticoagulant effect of the LMWH enoxaparin in healthy subjects.
Our preclinical portfolio includes next-generation defensin-mimetic compounds, which have shown potent activity targeting:
Gram-negative bacteria
Tuberculosis
Malaria
Foodborne pathogens
Biodefense pathogens
Fungal infections
We are leveraging our antimicrobial expertise by developing PolyCides®, antimicrobial additives to materials, such as cosmetics, plastics, textiles and dental products (PolyDentix™), to create self-sterilizing products and surfaces.